Funding profile · Functional genomics tools

Biocartesian

No SEC Form D has been found for Biocartesian. Two data firms report about $500,000 raised across a Y Combinator allocation and one angel check; a third reports no funding on record at all. Here is what each source actually says, set side by side.

$500KTotal raised, per PitchBook and Tracxn (aggregator estimate)
$0Funding on record, per GetLatka (aggregator estimate)
0SEC Form D filings found under the company’s name
2Named investors across all sources: Y Combinator, Bullock Capital

Data as of September 25, 2026. Company-reported figures are labeled; most figures here come from third party data aggregators, not company disclosures or SEC filings.

Rounds at a glance

When Round Amount Investors Source
Jan 2024 Accelerator or incubator allocation Not disclosed Y Combinator PitchBook
2024 Seed (single round, per Tracxn) $500,000 total, exact date and structure not broken out Not named Tracxn
Aug 2025 Angel (individual) Not disclosed Bullock Capital PitchBook
As of Sep 2026 No funding on record $0 None listed GetLatka

What the filings show

Nothing. A search of SEC EDGAR’s company database and its full text search index for the name “biocartesian” returned no Form D and no other filing, as of September 25, 2026. That is not unusual for a very small, YC scale seed company: an offering made under Section 4(a)(2) rather than Regulation D triggers no Form D at all, and a small SAFE or convertible note round sometimes goes unfiled until a priced round follows. It does mean that every dollar figure on this page comes from a data aggregator’s own research or estimate, not from a primary regulatory record.

Reading the aggregators

  1. Two firms agree on a number, but not on its shape.PitchBook and Tracxn each report $500,000 in total funding. PitchBook breaks that into two separate events, a January 2024 accelerator allocation, almost certainly the standard Y Combinator deal, and an August 2025 angel check from a group called Bullock Capital. Tracxn instead describes one seed round in 2024. Neither describes exactly how the other’s structure would net out to the same $500,000 total, and neither cites a primary source.
  2. A third firm reports nothing.GetLatka, which separately estimates the company’s 2025 revenue at about $330,000, states plainly that it has no funding information for Biocartesian. That is a direct gap against the PitchBook and Tracxn figures, not just a difference in emphasis.
  3. Y Combinator itself confirms only the accelerator, not a dollar figure.Y Combinator’s own company page and launch post confirm Biocartesian went through the Summer 2024 batch and name no other investor. YC’s standard batch deal is public information but is not restated on the company’s YC page, so the $500,000 figure cannot be checked against YC’s own materials.
  4. Bullock Capital is a real, small angel investment vehicle, per its own website and PitchBook’s separate investor profile, but no press release, blog post or SEC filing describing its investment in Biocartesian was found independent of the PitchBook listing itself.
  5. The Capital Readiness Program is not investment.The University City Science Center’s April 2026 selection of Biocartesian for its Capital Readiness Program cohort is a non-equity, grant-funded bootcamp on fundraising and governance, not a funding event, and should not be read as capital raised.

Commercial signals

Signal Detail Source type
Team size About 3 employees, consistent across Tracxn and PitchBook as of 2026. Independent
Estimated revenue GetLatka estimates about $330,000 in 2025 revenue, an estimate rather than a company disclosure. Independent estimate
Named customers Company materials describe customers only generically, as discovery teams and pharma research teams. No named pharma or biotech customer found. Not found
Non-dilutive support Selected for Cohort 11 of the University City Science Center’s Capital Readiness Program, a free, five day fundraising and governance bootcamp, April 2026. Independent
Underlying IP Co-founder Ian Dardani is first author on the clampFISH 2.0 RNA detection method published in Nature Methods, 2022, from his UPenn dissertation, which the company’s current ARADIA product extends. Public record

What to watch

  • A Form D or other SEC filing that would confirm any of the aggregator-reported figures with a primary source.
  • Whether GetLatka’s zero funding figure or PitchBook and Tracxn’s $500,000 figure gets corrected as more data becomes available.
  • A named pharma or biotech customer, which no source reviewed here provides.
  • Whether the company’s headquarters settles in San Francisco, Philadelphia, or both; the split shows up in this funding picture too, since Bullock Capital and the Science Center’s Capital Readiness Program both point toward Philadelphia.

The Biocartesian story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Dropprint Genomics: Also in Drug Discovery and Delivery. A San Francisco startup that built computational infrastructure and a database of over a million immune cells to make single cell genomics cheaper to run
  • Algen Biotechnologies: Also in Drug Discovery and Delivery. A CRISPR and machine learning platform for choosing drug targets, spun out of Jennifer Doudna’s Berkeley lab in 2018
  • CellChorus: Also in Drug Discovery and Delivery. A University of Houston spinout that films immune cells one at a time and scores how well each one kills
  • Sixfold Bioscience: Also in Drug Discovery and Delivery. A London company that set out to deliver RNA drugs everywhere except the liver

Sources

  1. Public recordSEC EDGAR full text search for “biocartesian,” Form D, no resultsSEC EDGAR · accessed Sep 25, 2026
  2. IndependentBiocartesian 2026 Company Profile, Valuation, Funding and InvestorsPitchBook · Jul 31, 2026
  3. IndependentBiocartesian company profileTracxn · accessed Mar 18, 2025
  4. IndependentBiocartesian Revenue 2025, $330K Est. ARR, no funding on recordGetLatka · Sep 2, 2026
  5. IndependentBiocartesian Funding, Complete AnalysisExtruct AI · Sep 25, 2024
  6. CompanyBiocartesian company pageY Combinator · accessed Aug 29, 2024
  7. IndependentScience Center Announces 10 Startups Selected for Cohort 11 of its Capital Readiness ProgramUniversity City Science Center · Apr 20, 2026
  8. IndependentBullock Capital angel investments pagebullockcapital.com · accessed Sep 25, 2026
  9. Public recordClampFISH 2.0 enables rapid, scalable amplified RNA detection in situNature Methods, Dardani et al. · 2022

Compiled from SEC records and published third party data as of September 25, 2026. No SEC Form D was found for Biocartesian; the funding figures on this page come from PitchBook, Tracxn and GetLatka, three independent data aggregators whose figures disagree with each other and are not confirmed by any primary filing. Healthcare Venture Capital Fund holds no position in Biocartesian. This page is not an offer to sell or a recommendation to buy any security.